Loading search results
RADIAUS
Alcoholism and Schizophrenia: A Translational Approach to Treatment
Sponsor study identifier
interventional
12
1 country
4
Study Start
December 2011
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2014
Actual (reported)Study Completion
September 2014
Actual (reported)Note: In June 2013, the study design was changed from a randomized controlled study of risperidone + despiramine vs. risperidone vs. placebo to an open label pre-post study of risperidone (or risperidone-like drug) + desipramine. The aims of the study were revised to read:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2014
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 16, 2011
Actual (reported)August 8, 2011
Actual (reported)December 2011
Date type not reportedThis date has not been verified as actual or estimated.
August 2014
Actual (reported)September 2014
Actual (reported)March 23, 2018
Actual (reported)Timeline Followback Assessing Number of Drinks Per Week
Alcohol/other substance use (including tobacco) will be assessed primarily by weekly self-report using the Timeline Followback (TLFB) method enhanced by procedures to strengthen the reliability and validity of this measure. It involves asking participants to retrospectively estimate their alcohol and other substance use.
Weekly for 14 weeks, using data from last 8 weeks
All participants will be treated with risperidone (or a risperidone-like agent including: risperidone long-acting, paliperdione, and paliperidone palmitate) at the time treatment with desipramine is initiated. The target dose of oral risperidone is 4mg though variations are allowed. The target dose of desipramine is 100mg.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Grouped treatment entry
Risperidone + Desipramine
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordUniversity of Massachusetts Medical School
Worcester, Massachusetts, 01605, United States
Michigan State University / Cherry Street Health Services
Grand Rapids, Michigan, 49503, United States
Dartmouth Medical School
Lebanon, New Hampshire, 03756, United States
University of South Carolina School of Medicine
Columbia, South Carolina, 29203, United States
Alan I Green, MD
Dartmouth-Hitchcock Medical Center
12 participants (actual enrollment reported by the registry).
First Submitted
June 16, 2011
First Posted
August 8, 2011
Study Start
December 2011
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
Primary Completion
August 2014
Actual (reported)Study Completion
September 2014
Actual (reported)Last Updated
March 23, 2018
Results First Posted
March 23, 2018
Record last verified: 2018-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: